The unfolded protein response and IRE1
The fitness and survival of eukaryotic organisms is contingent upon the fidelity of protein biosynthesis within their cells. Loss-offunction mistakes in protein folding damage cellular efficiency, whilst proteotoxic gain-of-function misfolding is associated with a heavy burden of human disease. In healthy cells, quality control mechanisms act to preclude toxicity and maintain protein folding homeostasis. However, in a diseased cell these same pathways can also be corrupted and the rectifying intentions subverted to cause dysfunction. 1 This apparent conflict and the convergence of multiple diseases on protein folding homeostasis has precipitated a need for new tools to understand the cellular response to perturbations in proteostasis, and garnered a broad effort for discovery.
Whilst protein biosynthesis begins in the cytosol of the cell, a large proportion of the eukaryotic proteome is trafficked through the luminal space of the endoplasmic reticulum (ER) soon after the initiation of synthesis. 2 Thus, the ribosomestudded rough ER is a major site of protein synthesis and this dominance is reflected in the complexity and sophistication of the systems operating to defend homeostasis in this compartment. In metazoans, accumulated unfolded or misfolded proteins are recognised by three transmembrane resident ER sensors: PERK (PKR-like endoplasmic reticulum eIF2a kinase), IRE1 (inositolrequiring enzyme 1) and ATF6 (activating transcription factor 6). These components adapt the ER to the folding client load using both translational and transcriptional interventions in a pathway collectively known as the unfolded protein response (UPR). Of these components, only IRE1 is conserved from fungus to man. It is the most studied element of the UPR, is linked most promiscuously to human disease, and its unusual dual enzymatic activity is a salient draw for chemical biologists.
IRE1 exists as two isoforms in mammals: IRE1a is ubiquitously expressed, whilst IRE1b, exhibiting only slightly differing enzymology, 3 is restricted to the epithelial cells of the intestinal tract. IRE1 comprises a tripartite structure with a luminal domain linked via a single transmembrane segment to the cytosolic kinase a Unilever Centre for Molecular Science Informatics, Department of Chemistry, and endoribonuclease domains. The luminal domain of IRE1 is closely related to that of PERK and detects the accumulation of unfolded proteins by one of several proposed mechanisms. Both the direct binding of unfolded clients to IRE1 4 and manipulation of the membrane composition 5 can impact on IRE1 activity. Additionally, the constitutively IRE1-bound molecular chaperone BiP (binding immunoglobulin protein) is dislocated away from IRE1 as unfolded clients accumulate. 6, 7 These conditions shift the monomeric pool of IRE1 towards oligomerization, triggering the kinase activity of IRE1 and transautophosphorylation of adjacent IRE1 protomers. 8 Phosphorylated IRE1 is activated, and is arranged in order to promote the endoribonuclease function that defines the role of IRE1 in the UPR. ER stress-activated IRE1 cleaves the latent mRNA for the XBP1 (X-box binding protein 1) transcription factor, liberating a 26 bp fragment and generating a frame-shifted transcript for XBP1 upon re-ligation. 9, 10 Processed XBP1 then upregulates the expression of genes encoding ER molecular chaperones, ER biosynthetic enzymes, translocation components, ER-associated degradation factors and ER membrane biogenesis enzymes.
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Thus, IRE1 responds to the saturation of ER client load with a broad regulatory programme that resolves ER stress by generating improved folding conditions, enhancing degradation and swelling the ER volume to thermodynamically favour folding over aggregation. 13 In addition to these functions, IRE1 can also cleave a subset of other ER-bound mRNAs, 14 in a process that may have links to cellular physiology, 15, 16 but which at present is only partially understood. Regulated IRE1-dependent mRNA decay (RIDD) attenuates protein load on the ER by preemptively degrading ER client mRNA, 17 and has also recently been linked to a surprising innate immune response to infection by cholera toxin. 18 In this study, RIDD products were shown to act as part of a signalling cascade to initiate a cytokine response to the toxin, where IRE1 was able to directly bind the cholera toxin to trigger the effect. IRE1 can also provide a node for pro-apoptotic signals emanating from the ER via the ASK1 (apoptosis signalling kinase) and JNK (c-Jun N-terminal kinase) pathways. 19, 20 This bipartisanship of IRE1 in the adaptive and apoptotic response of the cell to unfolded protein stress hints at a complex relationship with disease and places the enzyme at a compelling nexus for pharmacological intervention. Metabolic diseases including type II diabetes mellitus, neurodegeneration, cancer and inflammatory diseases have all been linked to the IRE1/XBP1 pathway, 1 and in most cases pathogenesis is linked with a hyperactive UPR.
Pharmacological inhibition of the IRE1 endonuclease
The enzymology and structure of IRE1 make it an ideal candidate for reverse chemical genetics. The kinase domain of IRE1 has been targeted by nucleotide analogues, allosterically inactivating the RNase of IRE1 and blocking high order assembly of the IRE1 multimers, 21 but direct inhibitors of the RNase have only been discovered following large-scale screening efforts.
Remarkably, each of these studies converged upon molecules with very similar chemistry. The mammalian protein was adapted to a FRET-derepression assay for high-throughput screening and libraries of >220 000 22 and >240 000 17 compounds were screened for kinetic disruption of the fluorescence signal. In a third programme, a cell-based XBP1-lufierase assay was used to screen >60 000 compounds for their effect on in vivo IRE1 activity. 23 The lead compounds selected following each independent effort yielded small hydrophobic molecules containing an orthohydroxyl aryl aldehyde moiety: the salicylaldehydes, 22 the coumarin 4m8C 17 and STF083010 23 ( Fig. 1) . Although the aldehyde moiety of STF083010 went undetected during the screening process, it is clear that the imine bond of the library compound rapidly hydrolyses in aqueous solution to liberate an active carbaldehyde-containing napthalene. 17, 24 Indeed, for each of these inhibitors of IRE1, the aldehyde moiety was initially masked in the library compound by an imine linkage ( Fig. 1) , an important consideration when trying to deconvolute the data returned from high-throughput screening efforts and to characterise lead compounds. The aldehyde moiety is key to inhibition and each of these compounds operates by formation of a Schiff base with at least one key residue in the IRE1 molecule. However, despite the covalent mode of these inhibitors, they appear to retain specificity for IRE1 both in vitro and in cellular studies. 17, 22, 23 The explanation for the surprising selectivity of the drugs was greatly aided by biochemical analysis of 4m8C and the application of in silico docking and molecular dynamics simulations to rationalise the structural implications for the drug-inhibited IRE1 molecule.
Molecular dynamics simulations & insights into IRE1 inhibition
The molecular dynamics (MD) approach provides a Newtonian physics-based framework in which to simulate motions of biomolecules at unparalleled temporal and spatial resolution. Typically, the structure of a protein, obtained experimentally via nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography, is embedded in a simulation unit cell containing a physiologically modelled salt solution, resulting in a system containing tens of thousands of atoms. 25, 26 The forces acting on each atom are calculated via a classical potential function or ''force field'' composed of simple equations containing terms for intra-and inter-molecular interactions, which may simplistically be likened to a collection of ''balls and springs''. Under the assumption that these forces are constant over a small time interval, they may be used to estimate accelerations, and hence new positions and velocities, of the atoms in the system, according to Newton's laws of motion. 27, 28 Repeating this cycle many millions of times enables propagation of a simulation trajectory, from which information concerning the dynamics and energetics of biomolecules may be gathered, complementing available experimental data. Continuing improvements in algorithms, force field parameters, and high-performance computing technologies have made it routinely possible to carry out accurate simulations of biomolecular systems over timescales of tens or hundreds of nanoseconds, or even beyond. 29 MD also provides an exciting opportunity to supplement the drug design process. Proteins are dynamic and flexible; they breathe, change shape, and respond to the presence of other molecules. 30 Simulations can identify conformational changes in biomolecules in response to ligand binding/release, 31, 32 and can help to discover and characterize novel druggable sites. [33] [34] [35] Simulations also make it possible to accurately predict thermodynamic properties such as ligand-binding free energies, via so-called ''alchemical'' transformation. In such approaches, the interaction between a drug and its environment are slowly ''annihilated'' during a series of MD simulations, in both the solvated, protein-bound and protein-free states. 25, 36, 37 Measuring the respective energetic changes DG protein,bind and DG water,bind during these processes enables ''completion'' of the thermodynamic cycle, yielding the relative free energy change for extracting a drug molecule from solvent and positioning it within the protein binding site -in other words, the binding free energy DG bind ( Fig. 2A) . Such calculations can yield extremely accurate results, but are computationally demanding, particularly as a result of their sensitivity to inadequate conformational sampling. Thus, they are generally of most use in the drug optimization stage, following lead compound discovery. A combination of molecular modelling, simulation, and thermodynamics calculations has recently been utilized to gain insights into the mechanism of inhibition of IRE1 by 4m8C, complementing and extending experimental observations. 17 The chemical properties of 4m8C allowed the covalent interaction of the drug with the enzyme to be directly observed by spectroscopy. This modification was further confirmed and mapped by high-performance liquid chromatography (HPLC)-linked mass spectrometry, revealing an unusually stable Schiff base at two mechanistically critical lysines. One of these (K907) is present in the endonuclease domain at the active site of IRE1 and is required for IRE1 RNase catalysis. 17, 38 The other lysine, K599, located within the kinase domain, plays a role in phosphate coordination and is common to all kinase domains. Curiously, only K907 was modifiable in vivo. Thus, two key questions concerning the specificity of 4m8C was posed by these observations: first, why does measurable Schiff-base formation by 4m8C 23 In each of the screening programmes, the hit compounds were initially selected from imine linked scaffolds (upper panels). These were subsequently found to hydrolyse during the aqueous in vitro assays to yield the carbaldehyde-containing active species (lower panels).
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Open Access Article. only occur at two out of a total of twenty-five lysine residues in its cytosolic domains? Second, why is the modifiability of K599 context-dependent? To begin to answer these questions, Cross et al. performed explicitly solvated, all-atom MD simulations of the ''apo'' uninhibited state of the IRE1 dimer. 17 The complete system amounted to a size on the order of a quarter of a million atoms, making these calculations computationally demanding. The first hint to the peculiar specificity of 4m8C came from an analysis of the exposed surface area accessible to solvent of the lysine residues present in IRE1. Most lysines exhibited an average exposed surface area of B90 Å 2 during simulation on the nanosecond timescale. This agrees reasonably well with a previous analysis of protein structures from the protein databank (PDB), showing that lysine is the most solvent-accessible of all amino acids, with a mean exposed area of B100 Å 2 . 39 With the exception of two residues buried at the dimer interface, the only lysines in IRE1 that did not follow this trend were K599 and K907, each with exposed areas of just B50 Å 2 . Only B10% of lysines in folded proteins tend to exhibit this degree of burial, and for comparison, fully exposed lysine possesses a surface area of over 200 Å 2 .
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Thus, whilst most lysines in the cytosolic domain of IRE1 are surface exposed and flexible, K599 and K907 remain somewhat shielded from bulk solvent. Following Schiff base formation by 4m8C at these sites, reduced ease of hydrolysis of the imine bond compared to other sites was hypothesized to lead to a low off-rate, helping to explain the selectivity. On the other hand, . In (A) and (B), DG water is the free-energy change associated with the unbound drug being annihilated (DG water,bind ) or with an unbound model lysine sidechain becoming deprotonated (DG water,deprot ). DG protein is the equivalent free-energy change in the protein-bound state for annihilation (DG protein,bind ) or deprotonation (DG protein,deprot ), respectively. In (A), measurement of these quantities enables calculation of the free-energy DG bind for drug binding along the * arm. In (B), the * arm represents DDG deprot , the relative free-energy difference for deprotonation between the protein-resident and solvated forms of lysine, which enables calculation of the pK a shift within the protein relative to the model compound, as illustrated in (C). 
Predicted mode of IRE1 inhibition
To gain further insights into the structural basis for IRE1 inhibition, possible 4m8C-inhibition modes were modelled, using a tailored protocol designed for the covalently-bound inhibitor involving extensive sampling and optimization in torsional-angle space around each rotatable bond of the Schiff base at K907. 17 A number of possible orientations for 4m8C
were identified via this approach, the most favourable (large and negative enthalpy of interaction) of which satisfied all possible interactions within the binding site. As shown in Fig. 3A , this involves a stacked conformation of one of the 4m8C coumarin rings against the sidechain of F889, along with two hydrogen-bonds to the sidechain of D885 and/or H910. The predicted location of 4m8C would be expected to interfere with catalysis and impede substrate binding, by forming a wedge positioned between the catalytic residues Y892 and H910. We now extend these observations to the other families of small, potent inhibitory molecules of IRE1: a hydrolysed carbaldehyde-containing napthalene analogue of STF-083010 23 and one of the most potent salicylaldehydes, 3-methoxy-6-bromo-sialicylaldehyde. 22 The same exhaustive conformational sampling and optimization protocol was used to identify favourably bound states of each to K907, as described previously. 17 In each case, a similar interaction mode was predicted for the most favourable orientation as for 4m8C ( Fig. 3B and C) . For the STF-083010 analogue, an almost identical conformation was observed, with comparable stacking of one of the rings against F889, and two hydrogen-bonds to D885. For the salicylaldehyde, a hydrogen-bond was formed with H910 to facilitate stacking of the inhibitor's single ring against F889, again leading to a similar inhibitory mode within the catalytic site. Thus, these independently identified aldehyde-containing small molecules appear to have converged upon a similar mechanism of inhibition.
To test the stability of this predicted binding mode, the modelled conformation of 4m8C bound to K907 was used to initiate multiple MD simulations of the inhibited IRE1 in solvent. 17 In each subsequent simulation replica, the 4m8C rings remained stacked against the sidechain of F889, and the inhibitor relaxed into a hydrophobic pocket formed by sidechains of nearby, nonpolar residues. Strikingly, this immersion of 4m8C within the hydrophobic pocket appeared to constrain the RNase active site, which by comparison, was relatively dynamic over tens of nanoseconds in the apo, unbound state. This would be expected to further slow the off-rate by reducing bulk water exchange and hence hydrolysis at the imine bond site.
Computational determination of IRE1 K907 pK a
The reduced solvent exposure of the K907 sidechain and the stable burial of bound 4m8C within a hydrophobic microenvironment are of great interest, since conditions of low polarity or polarizability can shift pK a values of internal ionizable residues including lysines 40 towards their unbound form. The e-amino group of K907 must be in its uncharged form in the first step of Schiff base formation, to enable nucleophilic attack on the 4m8C carbaldehyde carbonyl. We therefore questioned whether the hydrophobic microenvironment accessible to K907, buried within the RNase active site, might down-shift its pK a , and thus increase the rate of Schiff base formation by 4m8C. To investigate this further, we note that the dissociation constant K a of a titratable group is related to the free energy change of deprotonation DG deprot in the following way: Fig. 3 IRE1 inhibition modes predicted for (A) 4m8C, 17 (B) napthalene analogue of STF-083010, 23 and (C) 3-methoxy-6-bromo-sialicylaldehyde. 22 The RNase domain is shown in cartoons format, with key residues highlighted in wireframe format and labelled. The binding conformation for each inhibitor was predicted via sampling and optimization in torsional-angle space around each Schiff base rotatable bond, using the CHARMM package 55 with the CHARMM22/CMAP 41 and CGenFF 56 forcefields for protein and inhibitor, respectively. Molecular graphics were generated using VMD. where k is the Boltzmann constant. The pK a may therefore be related to DG deprot :
As discussed above, alchemical transformation within an MD simulation framework may be used to estimate free-energy changes associated with, for example, repositioning a solvated drug molecule into a protein binding site, as part of a thermodynamic cycle (Fig. 2A) . In the same way, the free-energy associated with deprotonation may be calculated, via annihilation of the proton associated with an ionizable site. Thus, according to Fig. 2B , calculation of the free energy for deprotonation of an ionisable residue in the protein (DG prot , deprot ) and for the model amino acid analogue in solvent (DG water , deprot ) enables estimation of a pK a shift, DpK a :
where DDG deprot ¼ DG protein;deprot À DG water;deprot
Two sets of free-energy calculations were therefore performed, of the complete IRE1 dimer in water (to estimate DG protein , deprot ), and of a lysine amino acid analogue in water (to estimate DG water , deprot ). In each case, 20-30 MD simulations of 3-4 ns each were performed, in which the system was gradually changed via a coupling parameter l, from state l = 0 (K907 protonated) to state l = 1 (K907 deprotonated). The respective free energy changes (averaged over both IRE1 monomers) could then be calculated as a sum of energies over the consecutive, intermediate states. Each simulation was carried out using the same conditions as described previously. 17 Briefly, the system contained dimeric IRE1
(PDB ID code 3P23) in complex with ADPÁMg
2+
, surrounded by a 0.1 M NaCl solution in a truncated octahedral box (B250 000 atoms total), and was described using the CHARMM22/CMAP 41 forcefield within the GROMACS 4.5 simulation package. 42, 43 As shown in Fig. 4 , the cumulative free energy change for deprotonation of isolated lysine in water (DG water , deprot = 73.1 AE 0.6 kcal mol À1 ) and of K907 in IRE1 (DG protein , deprot = 68.2 AE 0.6 kcal mol À1 ) yields DDG deprot = À4.9 AE 0.8 kcal mol À1 . We therefore estimate a pK a down-shift for K907 within IRE1 of 3.6 AE 0.6 units. Thus, relative to the model pK a of lysine in water (B10.5), the pK a of the K907 sidechain is likely to lie at around 7, and macroscopically, it will exist in IRE1 molecules as an equal population of charged and uncharged states at neutral pH. At the structural level (Fig. 4) , this pK a shift results from the ease with which K907 becomes buried within the deep hydrophobic pocket upon deprotonation, combined with the dynamic nature of the RNase active site entrance, as observed previously. 17 For example, upon complete deprotonation, the e-amino group of K907 moves further into the binding site, and its mean distance from D885 and H910 at the active site entrance increases, respectively, from 0.5 AE 0.2 Å and 0.2 AE 0.1 Å during simulation at l = 0, to 0.7 AE 0.2 Å and 0.5 AE 0.1 Å during simulation at l = 1.
Experimental support for this shift in pK a at lysine 907 is found when the efficiency of 4m8C modification of IRE1 is measured in vitro. Binding of the fluorescent compound to IRE1 can be visualised in-gel following UV irradiation, 17 and we find that whilst this modification is strictly pH-dependent, reactivity is observed even in conditions where lysines on IRE1 are expected to be deprotonated (Fig. 5) . Substantially increased binding of 4m8C is found when the buffered conditions match the pK a for lysine in solution where the compound is able to react with the other nucleophiles on IRE1 (>pH 10, Fig. 5, lane  11) . Hence, the pK a perturbed K907 is able to participate in Schiff base formation even at pH 7. Overall, our results suggest that K907 is more easily deprotonated than usual under normal cell conditions, consistent with RNase domain is shown in cartoons format. Hydrophobic residues within the binding pocket, along with key ionizable sidechains, are shown in wireframe format. Molecular graphics were generated using VMD. 57 The free-energy curves were generated using the Bennett acceptance ratio (BAR) method with soft-core potentials. DG protein was calculated using l windows 0.05 or 0.025 apart, between 0 r l o 0.7 and 0.7 r l r 1.0 respectively. DG model used l windows 0.05 apart between 0 r l r 1.0. Extensive energy minimisation followed by 0.2 ns equilibration was performed, prior to the production run for each window. Each simulation was run under conditions of constant temperature (298 K) 58 and pressure (1 atm), 59 using a 2 fs time step with LINCS constraints applied to bond lengths. 60 Electrostatics were calculated using the Particle-Mesh Ewald algorithm, and Van der Waals interactions were smoothly switched off from 10 to 12 Å.
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Open it being buried in a hydrophobic microenvironment that is partially dehydrated. This would lead to increased nucleophilicity of the K907 e-amino group, an increased rate of Schiff base formation with 4m8C, and a slow off-rate.
RNase catalysis in IRE1
In addition to the contribution to the Schiff base formation, a shifted pK a at K907 may have consequences for the mechanism of RNase catalysis by IRE1. Structural analysis of the yeast apoenzyme provided the first detailed clues into the mechanism of endoribonucleolytic scission in IRE1. 44 Catalysis by IRE1 is likely to proceed via a general acid-base mechanism, similar to that found for Archaeglobus fulgidus splicing endonuclease and yielding a 2 0 ,3 0 -cyclic phosphate product. 44, 45 His1061/Tyr1043 in yeast IRE1 would therefore form a proton transfer acid-base pair for scission, homologous to His257/ Tyr246 of the splicing endonuclease and analogous to His pairs in both RNase A and T1. R1056 in yeast IRE1 stabilises the transition state by hydrogen bond formation with the non-bridging oxygen during proton transfer to enact RNA cleavage. 46, 47 The contribution to catalysis for the two core catalytic residues in ScIre1p has been quantitatively demonstrated, 46 and elements of the active site are also well conserved to mammalian IRE1 and RNase L. This core mechanism therefore likely largely persists through evolution, although some notable divergence in the active site from the yeast to the human enzyme is apparent. In the structure for the human enzyme for example, 48 the conserved HsIRE1a R902 is found displaced from the core catalytic pair whilst the sidechain of K907 is oriented towards the His/Tyr intersection. Thus, in mammalian IRE1, K907 appears to be better placed to support transition state stabilisation than R902, and given the pronounced reduction of the pK a it is likely to perform this role better, forming a stronger hydrogen bond to the cleavage intermediate. A similar arrangement is found in RNase A where K41 is pK a perturbed, lowering the free energy of the transition state to promote catalysis. 49 Our computationally derived model may therefore suggest a mechanistic rationale for excelled catalysis by human IRE1 as compared to the budding yeast enzyme -a more potent mammalian enzyme provides the necessary depth to cleavage for the emergence of RIDD and the physiological consequences of lapsed specificity. Interestingly, although the S. cerevisiae IRE1 does not appear to conduct a RIDD-like process, the fission yeast enzyme does. 50 Solution of the S. Pombe IRE1 structure might therefore provide important new clues to the evolution of IRE1 cellular function.
Outlook
Large-scale screening efforts have led to the independent discovery of several hydrophobic inhibitors that target the IRE1 RNase domain. Each molecule contains a common aldehyde moiety, whose presence enables selective Schiff base formation with K907. 17, 22, 23 A combination of biochemical analysis, molecular modelling, and simulation has provided a rationale for this mode of inhibition, and in particular, immersion of each molecule within the hydrophobic pocket of the RNase domain appears to contribute to specificity. As well as slowing the offrate by protecting the imine bond against hydrolysis, we now believe that this binding mode also directly influences the chemistry of inhibition. The K907 sidechain must be in its uncharged form in the first step of Schiff base formation, to facilitate nucleophilic attack on the inhibitor. The surrounding, nonpolar microenvironment has indeed been shown to perturb the pK a of K907 to around 7. This would favour deprotonation and increase its intrinsic nucleophilicity, making it significantly reactive even at neutral pH, as supported by our experimental data. This is not unprecedented. A lysine within an aldolase catalytic antibody was previously demonstrated to proceed via a Schiff base intermediate; its deeply buried location within a hydrophobic pocket perturbed its pK a below 7. 51 Moreover, such shifts can be functionally important in catalysis, and indeed, measurements based upon engineered staphylococcal nuclease constructs have revealed down-shifts in internal lysine residues by as much as 5 pK a units. 52 In this context, our results also hint at the source of differing catalytic efficiencies in human and yeast IRE1. Uncovering the divergence in enzymology in the active site of IRE1 by both computational and biochemical means may therefore provide important new understanding of these cellular pathways.
As well as providing a useful new tool for manipulating IRE1 in vivo and in vitro, these newly discovered classes of inhibitors provide a possible route to treatments for diseases associated with proteostasis. For many years, covalent drugs have stimulated anxiety in the pharmaceutical industry due to their potential for offtarget reactivity. Nevertheless, several of the top-selling drugs are covalent inhibitors of their targets (e.g. proton pump inhibitors), leading to suggestions that we are likely to see a resurgence of interest in covalent drugs. 53 Whilst existing covalent drugs have tended to be discovered through biological screening assays, it seems possible that a more targeted approach may now be possible. As suggested by Singh et al., design could involve identifying non-reversible inhibitors for a specific target site, followed by adaptation of the structure for covalent binding. 53 Given the emerging perspective that pK a -shifted lysines in buried protein cavities may be more common than expected, we could therefore envisage a general drug design pipeline which incorporates the identification of nearby lysine residues, combined with simulation-based pK a shift calculations, towards selective Schiff-base inhibition.
